Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
about
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateMenopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival.Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers
P2860
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@ast
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@en
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@nl
type
label
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@ast
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@en
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@nl
prefLabel
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@ast
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@en
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@nl
P2860
P50
P3181
P356
P1476
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
@en
P2093
Fabrizio Fontana
Patrizia Limonta
P2860
P3181
P356
10.3389/FENDO.2016.00140
P407
P577
2016-10-26T00:00:00Z